Mechanistically, we showed that targeting NEAT1 increased the response to PARPi in vitro in serous ovarian cancer by directly influencing the RAD51-HR axis, further indicating the critical role of NEAT1 in improving OC chemotherapy sensitivity and providing promising treatment strategy for the application of NEAT1 in OC. Here, NEAT1 is linked to ovarian serous adenocarcinoma.